ES2644818T3 - Tratamiento de fibrilación auricular - Google Patents

Tratamiento de fibrilación auricular Download PDF

Info

Publication number
ES2644818T3
ES2644818T3 ES10832058.1T ES10832058T ES2644818T3 ES 2644818 T3 ES2644818 T3 ES 2644818T3 ES 10832058 T ES10832058 T ES 10832058T ES 2644818 T3 ES2644818 T3 ES 2644818T3
Authority
ES
Spain
Prior art keywords
sulcardine
dose
administration
infusion
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10832058.1T
Other languages
English (en)
Spanish (es)
Inventor
Gary T. Elliot
Yiping Wang
Donglu Bai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica
Huya Bioscience International LLC
Original Assignee
Shanghai Institute of Materia Medica
Huya Bioscience International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica, Huya Bioscience International LLC filed Critical Shanghai Institute of Materia Medica
Application granted granted Critical
Publication of ES2644818T3 publication Critical patent/ES2644818T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ES10832058.1T 2009-11-17 2010-11-16 Tratamiento de fibrilación auricular Active ES2644818T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26192509P 2009-11-17 2009-11-17
US261925P 2009-11-17
PCT/US2010/056857 WO2011062906A2 (en) 2009-11-17 2010-11-16 Treatment of atrial fibrillation

Publications (1)

Publication Number Publication Date
ES2644818T3 true ES2644818T3 (es) 2017-11-30

Family

ID=44060290

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10832058.1T Active ES2644818T3 (es) 2009-11-17 2010-11-16 Tratamiento de fibrilación auricular
ES17182709T Active ES2929185T3 (es) 2009-11-17 2010-11-16 Uso de la sulcardina para el tratamiento de la fibrilación auricular

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17182709T Active ES2929185T3 (es) 2009-11-17 2010-11-16 Uso de la sulcardina para el tratamiento de la fibrilación auricular

Country Status (10)

Country Link
US (1) US8541464B2 (cg-RX-API-DMAC10.html)
EP (2) EP3311810B1 (cg-RX-API-DMAC10.html)
JP (2) JP6116908B2 (cg-RX-API-DMAC10.html)
CN (3) CN102665714A (cg-RX-API-DMAC10.html)
DK (2) DK3311810T3 (cg-RX-API-DMAC10.html)
ES (2) ES2644818T3 (cg-RX-API-DMAC10.html)
HU (2) HUE060876T2 (cg-RX-API-DMAC10.html)
PL (2) PL2501381T3 (cg-RX-API-DMAC10.html)
RS (1) RS63699B1 (cg-RX-API-DMAC10.html)
WO (1) WO2011062906A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541464B2 (en) * 2009-11-17 2013-09-24 HUYA Biosciences International LLC Treatment of atrial fibrillation
WO2011062903A2 (en) * 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts
SG2013035662A (en) 2013-05-08 2014-12-30 Menicon Singapore Pte Ltd Systems and methods for printing on a contact lens
WO2020123824A1 (en) 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
CN112516136B (zh) * 2019-09-17 2024-03-01 中国科学院上海药物研究所 硫酸舒欣啶在制备抗心衰产品中的应用
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
CN114984004B (zh) * 2022-05-25 2023-09-12 扬州中宝药业股份有限公司 硫酸舒欣啶在制备抗脓毒症药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) * 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
US8541464B2 (en) * 2009-11-17 2013-09-24 HUYA Biosciences International LLC Treatment of atrial fibrillation
WO2011062903A2 (en) * 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts

Also Published As

Publication number Publication date
US8541464B2 (en) 2013-09-24
JP2013511473A (ja) 2013-04-04
JP6116908B2 (ja) 2017-04-19
EP3311810B1 (en) 2022-07-27
DK3311810T3 (da) 2022-10-24
WO2011062906A8 (en) 2012-02-09
CN105362264A (zh) 2016-03-02
HK1254495A1 (en) 2019-07-19
WO2011062906A9 (en) 2011-10-06
WO2011062906A2 (en) 2011-05-26
PL3311810T3 (pl) 2022-12-05
JP2016028054A (ja) 2016-02-25
PL2501381T3 (pl) 2018-02-28
CN104324024A (zh) 2015-02-04
EP2501381A2 (en) 2012-09-26
CN102665714A (zh) 2012-09-12
EP2501381A4 (en) 2013-06-12
HUE034007T2 (en) 2018-01-29
RS63699B1 (sr) 2022-11-30
US20120309810A1 (en) 2012-12-06
HUE060876T2 (hu) 2023-04-28
EP3311810A1 (en) 2018-04-25
DK2501381T3 (da) 2017-11-06
EP2501381B1 (en) 2017-07-26
ES2929185T3 (es) 2022-11-25

Similar Documents

Publication Publication Date Title
ES2929185T3 (es) Uso de la sulcardina para el tratamiento de la fibrilación auricular
ES2325207T3 (es) Combinacion que comprende valsartan, amlodipina e hidroclorotiazida.
ES2569123T3 (es) Infusión lenta de sulcardina y sus sales
ES2935684T3 (es) Formulaciones de epinefrina intranasales y métodos para el tratamiento de enfermedades
WO2002051412A1 (en) Medicinal compositions containing aspirin
JP2013511473A5 (cg-RX-API-DMAC10.html)
ES2924728T3 (es) Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas
JP2013511472A5 (cg-RX-API-DMAC10.html)
JP2012532852A (ja) ２型糖尿病における食後高血糖の経頬粘膜治療の方法、および当該治療に用いられる医薬組成物
US20210369648A1 (en) Cysteamine zinc complex and method of using a cysteamine zinc complex
ES2988478T3 (es) Agente profiláctico y/o terapéutico para la demencia
ES2299738T3 (es) Composicion farmaceutica que combina el tenatoprazol y un antagonista de los receptores h2 a la histamina.
US20150272872A1 (en) Oromucosal Apomorphine Compositions
HK1254495B (en) Use of sulcardine for the treatment of atrial fibrillation
JPH11511479A (ja) １，２，４−ベンゾトリアジンオキシド製剤
KR20230012515A (ko) 유익한 치료방법
HK1176859B (en) Treatment of atrial fibrillation
HK1176859A (en) Treatment of atrial fibrillation
ES2483940T3 (es) Un nuevo régimen de dosificación para compuestos moduladores del canal iónico para el tratamiento de la fibrilación auricular aguda en un ser humano
PH26019A (en) Use of TP-receptor antagonists to modify the action of myofibrolasts
EP4698146A1 (en) Liquid and solid compositions of imipridone derivatives
JP2002255815A (ja) 新規な微小循環改善剤